News - Endo Pharmaceuticals, Watson Pharmaceuticals


Popular Filters

Actavis debuts generic Pariet in Europe; Impax challenges Opana ER patent


Switzerland-based generic drugmaker Actavis, now wholly-owned by the USA's Watson Pharmaceuticals (NYSE:…

ActavisEndo PharmaceuticalsGastro-intestinalsGenericsGrunenthalImpax LaboratoriesJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaOpana ERParietPatentsThoRx LabsWatson Pharmaceuticals

US patent settlements of Xopenex and Lidoderm


US generics drug major Mylan (Nasdaq: MYL) has entered into a settlement agreement with Sunovion Pharmaceuticals,…

Dainippon Sumitomo PharmaEndo PharmaceuticalsGenericsLidodermMylan LaboratoriesNeurologicalNorth AmericaPatentsRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenex

Back to top